MARKET

NKTR

NKTR

Nektar Therapeutics
NASDAQ
24.94
-1.73
-6.49%
After Hours: 24.93 -0.01 -0.04% 19:59 07/18 EDT
OPEN
26.62
PREV CLOSE
26.67
HIGH
27.72
LOW
24.51
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
37.38
52 WEEK LOW
6.48
MARKET CAP
415.57M
P/E (TTM)
-2.6207
1D
5D
1M
3M
1Y
5Y
1D
Nektar call volume above normal and directionally bullish
TipRanks · 2d ago
H.C. Wainwright Reaffirms Their Buy Rating on Nektar Therapeutics (NKTR)
TipRanks · 6d ago
Weekly Report: what happened at NKTR last week (0707-0711)?
Weekly Report · 6d ago
Nektar Therapeutics Price Target Raised to $85.00/Share From $60.00 by B. Riley Securities
Dow Jones · 07/08 18:08
Nektar Therapeutics Is Maintained at Buy by B. Riley Securities
Dow Jones · 07/08 18:08
B. Riley Securities Maintains Buy on Nektar Therapeutics, Raises Price Target to $85
Benzinga · 07/08 17:58
Nektar price target raised to $85 from $60 at B. Riley
TipRanks · 07/08 13:35
NEKTAR THERAPEUTICS <NKTR.O>: B. RILEY RAISES TARGET PRICE TO $85 FROM $60
Reuters · 07/08 02:54
More
About NKTR
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Webull offers Nektar Therapeutics stock information, including NASDAQ: NKTR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NKTR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NKTR stock methods without spending real money on the virtual paper trading platform.